Drug price review board bill
Executive Summary
HR 1434, introduced by Rep. Durbin (D-Ill.) March 23, would establish a board, modeled on the Canadian price review board, that would collect pricing information and R&D, marketing and manufacturing costs, publish its findings, and give the board power to revoke a drug's patent if the price is found excessive. Durbin wants his proposal or a similar concept included in Clinton's health care package. The bill, which currently has four sponsors, was referred to the Energy & Commerce Committee.